Arbutus Biopharma Missed Consensus Estimates

Arbutus Biopharma (ABUS) reported a loss of $0.13 per share on revenue of $1.76 million for the first quarter ended March 2025. The consensus estimate was a loss of $0.09 per share on revenue of $1.61 million. The company missed consensus estimates by 44.44% while revenue grew 15.14% on a year-over-year basis.

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases.